TROP2 location may predict lung cancer outcomes with datopotamab deruxtecan

Patients receiving datopotamab deruxtecan whose lung cancer samples tested positive on a measure of TROP2 protein location lived longer without their cancer progressing than those with negative samples. Median time without progression was 7.2 months versus 4.0 months, with a hazard ratio of 0.40 (95% confidence interval 0.25-0.64). The measure was validated in nonsquamous non-small-cell lung cancer without actionable genomic alterations, genetic changes that can guide treatment choices.
The hazard ratio compares the rate of cancer progression or death between the positive and negative groups. The confidence interval gives the range of uncertainty around that estimate.
The same pattern was absent among patients receiving docetaxel, the other treatment assessed in TROPION-Lung01. Median time without progression was 4.1 months for patients with positive samples versus 4.4 months for those with negative samples. The authors said the findings indicate that the measure may help predict outcomes with datopotamab deruxtecan.
Datopotamab deruxtecan combines an antibody targeting TROP2, a cell surface protein, with a drug. Conventional visual scoring of TROP2 staining by pathologists does not predict response to this class of treatment in non-small-cell lung cancer, according to the authors.
The researchers developed a computer-based method to measure TROP2 staining in individual cancer cells and their internal compartments. Their normalized membrane ratio compares TROP2 at the cell membrane with the combined amount at the membrane and in the cytoplasm, the material inside the cell.
The ratio was developed using samples from 115 patients with advanced non-small-cell lung cancer in TROPION-PanTumor01. The threshold for a positive result was then optimized and validated in 221 patients with nonsquamous disease without actionable genomic alterations. This intended-use population came from 352 patients whose samples were suitable for biomarker assessment in TROPION-Lung01.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].